<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The clinical outcomes, including adverse events, in 34 unresectable advanced <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> patients with <z:mp ids='MP_0002169'>wild-type</z:mp> K-ras, who were treated with bevacizumab and <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi>-based chemotherapy as a first-line treatment, were analyzed for confirmation of the effectiveness and safety of this treatment </plain></SENT>
<SENT sid="1" pm="."><plain>The response rate of the patients was 44% (complete remission, 2 patients; and partial remission, 13 patients) </plain></SENT>
<SENT sid="2" pm="."><plain>The median progression-free survival and overall survival in these patients was 11.1 and 25.1 months, respectively </plain></SENT>
<SENT sid="3" pm="."><plain>Adverse events of greater than grade 3 were observed in 18 patients </plain></SENT>
<SENT sid="4" pm="."><plain>Of these patients, 10 exhibited grade 3/4 <z:hpo ids='HP_0001875'>neutropenia</z:hpo>, and 6 had <z:hpo ids='HP_0009830'>peripheral neuropathy</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Our results were similar to those of randomized phase III trials from abroad, including those using anti-epidermal growth factor receptor antibody, with respect to effectiveness and safety </plain></SENT>
<SENT sid="6" pm="."><plain>Furthermore, patients with <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastasis</z:e> had poor prognosis compared to those with <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> to organs other than the liver </plain></SENT>
<SENT sid="7" pm="."><plain>Further analysis will be required to better understand these results </plain></SENT>
</text></document>